Minimal Residual Disease Market Trends 2025–2029: Forecasts for Key Growth Segments

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Does The Market Size Of The Minimal Residual Disease Industry Compare Between 2025 And 2029?

The minimal residual disease market has experienced rapid expansion recently. It is projected to increase from $1.78 billion in 2024 to $2.01 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.6%. Historically, this growth has been driven by several factors, including the increasing number of cancer patients, enhanced research and development spending, improved healthcare affordability, the rising prevalence of blood cancer, and greater public awareness.

The minimal residual disease market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $3.19 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 12.3%. Factors contributing to this growth during the forecast period include an increasing incidence of cancer patients, an uptick in governmental awareness campaigns, enhanced healthcare accessibility, growing disposable incomes within developing nations, and efforts by governmental bodies to raise cancer awareness. Key trends anticipated during this period encompass progress in next-generation sequencing (NGS) technology, the establishment of standardized MRD testing, the integration of personalized MRD monitoring, innovations in liquid biopsy technologies, and the emergence of minimal residual disease-targeted therapies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21224&type=smp

What Are The Key Drivers Of Growth In The Minimal Residual Disease Market?

The projected expansion of the minimal residual disease market going forward is expected due to the rising incidence of cancer. Cancer refers to a collection of illnesses marked by the uncontrolled multiplication and dispersion of atypical cells throughout the body. This growing prevalence of cancer can be attributed to several factors, including an aging demographic, heightened exposure to environmental cancer-causing agents, detrimental lifestyle choices, and inherent genetic susceptibilities. The increasing number of cancer cases fuels the demand for precise MRD testing, which identifies any remaining cancer cells, thus enabling prompt therapeutic action and tailored patient care. This improves the ability to predict relapse and leads to better patient outcomes. As an illustration, data from May 2024, provided by the National Cancer Institute (NCI), a US-based government agency, indicated that in 2022, nearly 20 million new cancer diagnoses and 9.7 million cancer-attributable fatalities occurred globally. Future forecasts for 2040 suggest these numbers will rise to an estimated 29.9 million new cases and 15.3 million cancer-related deaths. Consequently, the expanding occurrence of cancer is a primary catalyst for the growth of the minimal residual disease market.

What Are The Key Segments In The Minimal Residual Disease Market?

The minimal residual diseasemarket covered in this report is segmented –

1) By Detection Target: Lymphoma; Leukemia; Solid Tumors; Other Detection Targets

2) By Test Technique: Flow Cytometry; Polymerase Chain Reaction (PCR); Next Generation Sequencing (NGS); Other Test Techniques

3) By End-User: Banking, Financial Services, And Insurance (BFSI); Retail And E-Commerce; Hospitals; Diagnostic Laboratories; Research Institutions

Subsegments:

1) By Lymphoma: Hodgkin Lymphoma; Non-Hodgkin Lymphoma

2) By Leukemia: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia

3) By Solid Tumors: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer

4) By Other Detection Targets: Multiple Myeloma; Neuroblastoma; Sarcomas

Which Market Trends Are Creating New Opportunities In The Minimal Residual Disease Industry?

Leading companies operating within the minimal residual disease (MRD) market are focusing their efforts on advancing in vitro diagnostic (IVD) test services, aiming to offer personalized therapy options for enhanced patient outcomes. An in vitro diagnostic (IVD) test service serves as a laboratory-based method for detecting residual cancer cells after treatment, thereby aiding in relapse prediction and therapy optimization. For instance, in December 2022, Adaptive Biotechnologies Corporation, a US-based biotechnology company, unveiled the clonoSEQ Assay to identify minimal residual disease (MRD) in patients with diffuse large B-cell lymphoma (DLBCL). This test examines circulating tumor DNA (ctDNA) in blood samples, providing a highly sensitive, non-invasive approach to monitor cancer progression and spot early signs of relapse. This assay furnishes clinicians with a more precise comprehension of a patient’s disease burden, facilitating the appropriate customization of treatment plans. It stands as the first minimal residual disease (MRD) test for diffuse large B-cell lymphoma (DLBCL) to gain Medicare coverage, thereby ensuring its widespread accessibility across all treatment regimens and various time points.

Which Leading Players Are Enhancing Their Minimal Residual Disease Market Presence Worldwide?

Major companies operating in the minimal residual disease market are Thermo Fisher Scientific Inc., Amgen Inc., Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Kite Pharma Inc., Natera Inc., Foundation Medicine Inc., NeoGenomics Inc., Guardant Health Inc., Grail LLC, Tempus AI Inc., Veracyte Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., Mission Bio Inc., ArcherDx Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/minimal-residual-disease-global-market-report

How Is Minimal Residual Disease Market Demand Varying Across Different Regions?

North America was the largest region in the minimal residual disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minimal residual disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Minimal Residual Disease Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21224&type=smp

Browse Through More Reports Similar to the Global Minimal Residual Disease Market 2025, By The Business Research Company

Inflammatory Bowel Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Chronic Disease Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report

Liver Diseases Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795